Medicines and PrescribingMedicines Shortages

A useful alternative depends on the patient.

When a medicine is short, the question is which alternatives could suit this patient; Reedley lays out the product and patient factors that matter; the prescriber chooses.

Illustrative demonstration · intended workflow

Interactive demonstration

Synthetic patient · pause, step and replay at any point

Medicines shortages: what a prescriber weighs

Synthetic data

Step 1 of 5 · Choose a scenario

Spironolactone 12.5 mg

  1. Choose a scenario
  2. Product identity
  3. Why the name is not enough
  4. What the prescriber decides
  5. The patient, not the name

Hypothetical supply scenario · every supply statement on this card is invented for the demonstration · no stock levels

Illustrative scenario · no patient record shown · considerations are general, not matched to a patient

Spironolactone 12.5 mg tablets are assumed unavailable. Hypothetical supply scenario for this demonstration. It does not describe current national supply.

The prescriber’s question

Could a 25 mg tablet, split in half, or a liquid stand in for a 12.5 mg tablet?

Product identity

One name, several products

Medicine nameSpironolactone

  • Spironolactone 12.5 mg Film-coated Tablets

    “Each 12.5 mg tablet contains 44 mg of lactose monohydrate”

    emc · §2 Composition · source

  • Aldactone 25 mg Film-Coated Tablets

    “Buff film-coated tablets with “SEARLE 39” engraved on one side.”

    emc · §3 Pharmaceutical form · source

  • Qaialdo 10 mg/ml Oral suspension

    “Two dosing syringes (a 1 ml syringe and a 5 ml syringe) are provided”

    emc · §4.2 Method of administration · source

  • Urospir 25 mg/5 ml Oral solution

    “Urospir is not bioequivalent to the innovator tablet.”

    emc · §4.2 Posology · source

Listed in no order of preference. Each product has its own product information; whether one can stand in for another is the prescriber’s decision.

Why the drug name is not enough

About the patient

Why it is prescribed

Dosing in the product literature differs by indication and is individually determined; the indication in the record matters before any strength change.

Source: Aldactone 25 mg Film-Coated Tablets — SmPC · emc

“Maintenance dose should be individually determined.”
Aldactone 25 mg Film-Coated Tablets — SmPCemc · §4.2 Posology · revised 01/2026Opened 13 Nov 2026Open the source

Renal function and potassium

The product literature warns about hyperkalaemia with impaired renal function; the patient’s recent results and monitoring are part of the picture.

Source: Aldactone 25 mg Film-Coated Tablets — SmPC · emc

“Hyperkalaemia may occur in patients with impaired renal function”
Aldactone 25 mg Film-Coated Tablets — SmPCemc · §4.4 Special warnings · revised 01/2026Opened 13 Nov 2026Open the source

Swallowing and handling

Whether the patient can split tablets reliably, or measure a liquid dose with a syringe, depends on the patient.

Source: Qaialdo 10 mg/ml Oral suspension — SmPC · emc

“Two dosing syringes (a 1 ml syringe and a 5 ml syringe) are provided”
Qaialdo 10 mg/ml Oral suspension — SmPCemc · §4.2 Method of administration · revised 21/07/2026Opened 13 Nov 2026Open the source

Excipients

Products differ in excipients, for example lactose content, which can matter for some patients.

Source: Spironolactone 12.5 mg Film-coated Tablets — SmPC · emc

“Each 12.5 mg tablet contains 44 mg of lactose monohydrate”
Spironolactone 12.5 mg Film-coated Tablets — SmPCemc · §2 Composition · revised 14/10/2025Opened 13 Nov 2026Open the source

About the product

Can this tablet be split?

Whether a tablet may be split is a product-by-product question: SPS guidance starts from what each product’s SmPC says. The Aldactone 25 mg SmPC describes the tablet’s markings without mentioning a score line.

Source: Checking if tablets can be crushed or capsules opened · NHS Specialist Pharmacy Service (last updated 6 Feb 2025); Aldactone 25 mg Film-Coated Tablets — SmPC · emc

“If the SmPC says a tablet can be split in half”
Checking if tablets can be crushed or capsules openedNHS Specialist Pharmacy Service (last updated 6 Feb 2025) · Scored tabletsOpened 13 Nov 2026Open the source
“Buff film-coated tablets with “SEARLE 39” engraved on one side.”
Aldactone 25 mg Film-Coated Tablets — SmPCemc · §3 Pharmaceutical form · revised 01/2026Opened 13 Nov 2026Open the source

Liquid is not the same as a tablet

One oral solution’s SmPC states it is not bioequivalent to the innovator tablet and that switching needs caution and increased clinical supervision.

Source: Urospir 25 mg/5 ml Oral solution — SmPC · emc

“Urospir is not bioequivalent to the innovator tablet.”
Urospir 25 mg/5 ml Oral solution — SmPCemc · §4.2 Posology · revised 10/07/2026Opened 13 Nov 2026Open the source
“If a switch is necessary, caution and increased clinical supervision are required.”
Urospir 25 mg/5 ml Oral solution — SmPCemc · §4.2 Posology · revised 10/07/2026Opened 13 Nov 2026Open the source

What the prescriber decides

The prescriber decides

  • Whether any alternative is appropriate for this patient
  • Which product, strength and form, and whether splitting is acceptable for this product and this patient
  • What monitoring and follow-up go with a change
  • How the change is explained to the patient

Reedley does not

  • Choose, rank or match an alternative to the patient
  • Say whether a specific tablet may be split
  • Convert doses between tablets and liquids
  • Show stock or availability

The patient, not the name

A useful alternative depends on the patient, not just the drug name.

Venlafaxine

  1. Choose a scenario
  2. Product identity
  3. Why the name is not enough
  4. What the prescriber decides
  5. The patient, not the name

Hypothetical supply scenario · every supply statement on this card is invented for the demonstration · no stock levels

Illustrative scenario · no patient record shown · considerations are general, not matched to a patient

A venlafaxine prolonged-release product is assumed unavailable. Hypothetical supply scenario for this demonstration. It does not describe current national supply.

The prescriber’s question

Is another venlafaxine product of the same strength interchangeable?

Product identity

One name, several products

Medicine nameVenlafaxine

  • Venlafaxine 75 mg tablets

    “in two divided doses taken with food”

    emc · §4.2 Posology · source

  • Efexor XL 150 mg hard prolonged release capsules

    “Treatment of generalised anxiety disorder.”

    emc · §4.1 Therapeutic indications · source

  • Venaxx XL 150 mg prolonged-release capsules, hard

    “Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of social anxiety disorder.”

    emc · §4.1 Therapeutic indications · source

  • Venladex XL 225mg Prolonged-Release Tablets

    “Tablets must be swallowed whole”

    emc · §4.2 Method of administration · source

  • Venlafaxine 37.5mg/5ml Oral Solution

    “taken with food, at approximately the same time each day”

    emc · §4.2 Method of administration · source

Listed in no order of preference. Each product has its own product information; whether one can stand in for another is the prescriber’s decision.

Why the drug name is not enough

About the patient

Indication

Licensed indications in section 4.1 differ between venlafaxine products, so the indication recorded for the patient matters.

Source: Efexor XL 150 mg hard prolonged release capsules — SmPC · emc; Venaxx XL 150 mg prolonged-release capsules, hard — SmPC · emc; Venlafaxine 75 mg tablets — SmPC · emc

“Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of social anxiety disorder. Treatment of panic disorder, with or without agoraphobia.”
Efexor XL 150 mg hard prolonged release capsules — SmPCemc · §4.1 Therapeutic indications · revised 10/2025Opened 13 Nov 2026Open the source
“Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of social anxiety disorder.”
Venaxx XL 150 mg prolonged-release capsules, hard — SmPCemc · §4.1 Therapeutic indications · revised 05/11/2026Opened 13 Nov 2026Open the source
“Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes.”
Venlafaxine 75 mg tablets — SmPCemc · §4.1 Therapeutic indications · revised 10/12/2025Opened 13 Nov 2026Open the source

Renal function

The product literature describes dose adjustment in severe renal impairment.

Source: Efexor XL 150 mg hard prolonged release capsules — SmPC · emc

“in patients with severe renal impairment (GFR < 30 ml/min)”
Efexor XL 150 mg hard prolonged release capsules — SmPCemc · §4.2 Posology · revised 10/2025Opened 13 Nov 2026Open the source

Gaps in supply

Any interruption matters: the product literature advises against abrupt discontinuation.

Source: Efexor XL 150 mg hard prolonged release capsules — SmPC · emc

“Abrupt discontinuation should be avoided.”
Efexor XL 150 mg hard prolonged release capsules — SmPCemc · §4.2 Posology · revised 10/2025Opened 13 Nov 2026Open the source

About the product

Release characteristics

Immediate-release tablets are taken in divided doses; prolonged-release products are taken once daily. Moving between them is described in the SmPC with individual adjustment.

Source: Venlafaxine 75 mg tablets — SmPC · emc; Efexor XL 150 mg hard prolonged release capsules — SmPC · emc

“in two divided doses taken with food”
Venlafaxine 75 mg tablets — SmPCemc · §4.2 Posology · revised 10/12/2025Opened 13 Nov 2026Open the source
“Individual dosage adjustments may be necessary.”
Efexor XL 150 mg hard prolonged release capsules — SmPCemc · §4.2 Posology · revised 10/2025Opened 13 Nov 2026Open the source

Tablet or capsule

Prolonged-release capsules and prolonged-release tablets are both to be swallowed whole and not divided.

Source: Efexor XL 150 mg hard prolonged release capsules — SmPC · emc; Venladex XL 225mg Prolonged-Release Tablets — SmPC · emc

“Capsules must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.”
Efexor XL 150 mg hard prolonged release capsules — SmPCemc · §4.2 Method of administration · revised 10/2025Opened 13 Nov 2026Open the source
“Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.”
Venladex XL 225mg Prolonged-Release Tablets — SmPCemc · §4.2 Method of administration · revised 04/11/2026Opened 13 Nov 2026Open the source

Licensed indications per product

Two prolonged-release capsule products of the same strength list different indications.

Source: Efexor XL 150 mg hard prolonged release capsules — SmPC · emc; Venaxx XL 150 mg prolonged-release capsules, hard — SmPC · emc

“Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of social anxiety disorder. Treatment of panic disorder, with or without agoraphobia.”
Efexor XL 150 mg hard prolonged release capsules — SmPCemc · §4.1 Therapeutic indications · revised 10/2025Opened 13 Nov 2026Open the source
“Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of social anxiety disorder.”
Venaxx XL 150 mg prolonged-release capsules, hard — SmPCemc · §4.1 Therapeutic indications · revised 05/11/2026Opened 13 Nov 2026Open the source

What the prescriber decides

The prescriber decides

  • Whether a different venlafaxine product suits this patient and indication
  • Whether to move between immediate-release and prolonged-release, and the dose if so
  • How to avoid a gap in treatment
  • Follow-up after any change

Reedley does not

  • Choose, rank or match a product to the patient
  • Convert doses between immediate-release and prolonged-release
  • Treat same-strength products as interchangeable
  • Show stock or availability

The patient, not the name

A useful alternative depends on the patient, not just the drug name.

Methylphenidate

  1. Choose a scenario
  2. Product identity
  3. Why the name is not enough
  4. What the prescriber decides
  5. The patient, not the name

Hypothetical supply scenario · every supply statement on this card is invented for the demonstration · no stock levels

Illustrative scenario · no patient record shown · considerations are general, not matched to a patient

A methylphenidate modified-release brand is assumed unavailable. Hypothetical supply scenario for this demonstration. It does not describe current national supply.

The prescriber’s question

Another long-acting methylphenidate of the same strength looks available. Is it interchangeable?

Product identity

One name, several products

Medicine nameMethylphenidate

  • Addepta XL 10 mg Modified-release capsule

    “an immediate release component (30% of the dose) and a modified release component (70% of the dose)”

    emc · §4.2 Posology · source

  • Affenid XL 18 mg prolonged release tablets

    “must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed”

    emc · §4.2 Method of administration · source

  • Equasym XL capsules (named by SPS)

    “No other MR products are bioequivalent to Equasym XL capsules”

    NHS Specialist Pharmacy Service (last updated 28 Aug 2025) · Do not switch Equasym XL capsules · source

Listed in no order of preference. Each product has its own product information; whether one can stand in for another is the prescriber’s decision.

Why the drug name is not enough

About the patient

Time-of-day symptom control

Products differ in how they release the medicine over the day; a change can alter symptom control at key times.

Source: Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations · MHRA Drug Safety Update (published 26 Sep 2022)

“Transferring to another formulation can result in changes in symptom management at key time periods during the day.”
Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulationsMHRA Drug Safety Update (published 26 Sep 2022) · Information on how formulations differOpened 13 Nov 2026Open the source

Preferences and routine

Dose frequency, side effects and individual needs are part of the conversation before any switch.

Source: Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations · MHRA Drug Safety Update (published 26 Sep 2022)

“consider patient preferences such as their individual needs, dose frequency, possible side effects”
Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulationsMHRA Drug Safety Update (published 26 Sep 2022) · Advice to healthcare professionalsOpened 13 Nov 2026Open the source

Specialist input

Product choice is case by case, with specialist input and the patient involved.

Source: Prescribing and switching between modified-release methylphenidate · NHS Specialist Pharmacy Service (last updated 28 Aug 2025)

“Product choice should be made on a case-by-case basis with specialist input”
Prescribing and switching between modified-release methylphenidateNHS Specialist Pharmacy Service (last updated 28 Aug 2025) · Involve patientsOpened 13 Nov 2026Open the source

About the product

Different release profiles

Long-acting products differ in dosing frequency, food effect and the amount and timing of the modified-release component.

Source: Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations · MHRA Drug Safety Update (published 26 Sep 2022)

“amount and timing of the modified-release component”
Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulationsMHRA Drug Safety Update (published 26 Sep 2022) · Advice to healthcare professionalsOpened 13 Nov 2026Open the source

Immediate-release share differs

For example, one capsule’s SmPC states a 30% immediate-release and 70% modified-release split; SPS lists that product as licensed but not yet launched in the UK.

Source: Addepta XL 10 mg Modified-release capsule — SmPC · emc; Prescribing and switching between modified-release methylphenidate · NHS Specialist Pharmacy Service (last updated 28 Aug 2025)

“an immediate release component (30% of the dose) and a modified release component (70% of the dose)”
Addepta XL 10 mg Modified-release capsule — SmPCemc · §4.2 Posology · revised 30/06/2026Opened 13 Nov 2026Open the source
“Addepta XL is licensed but not yet launched in the UK.”
Prescribing and switching between modified-release methylphenidateNHS Specialist Pharmacy Service (last updated 28 Aug 2025) · Products and their equivalenceOpened 13 Nov 2026Open the source

How it is taken

Some capsules may be opened and sprinkled on soft food; some tablets are to be swallowed whole, not chewed, divided or crushed.

Source: Addepta XL 10 mg Modified-release capsule — SmPC · emc; Affenid XL 18 mg prolonged release tablets — SmPC · emc

“the capsule may be opened and the capsule contents sprinkled onto a small amount (tablespoon) of soft food”
Addepta XL 10 mg Modified-release capsule — SmPCemc · §4.2 Method of administration · revised 30/06/2026Opened 13 Nov 2026Open the source
“must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed”
Affenid XL 18 mg prolonged release tablets — SmPCemc · §4.2 Method of administration · revised 16/10/2025Opened 13 Nov 2026Open the source

Not all are bioequivalent

SPS describes which modified-release products it considers bioequivalent, names one that has no bioequivalent, and advises against mixing brands to make up a dose.

Source: Prescribing and switching between modified-release methylphenidate · NHS Specialist Pharmacy Service (last updated 28 Aug 2025)

“No other MR products are bioequivalent to Equasym XL capsules”
Prescribing and switching between modified-release methylphenidateNHS Specialist Pharmacy Service (last updated 28 Aug 2025) · Do not switch Equasym XL capsulesOpened 13 Nov 2026Open the source
“avoid mixing between different brands to achieve the required daily dose”
Prescribing and switching between modified-release methylphenidateNHS Specialist Pharmacy Service (last updated 28 Aug 2025) · Actions during supply disruptionOpened 13 Nov 2026Open the source

What the prescriber decides

The prescriber decides

  • Whether any switch is appropriate, with specialist input and the patient involved
  • Which product and dose
  • The counselling the patient needs about timing and food
  • Follow-up after any change

Reedley does not

  • Choose, rank or match a product to the patient
  • State dose equivalences between products
  • Treat same-strength products as interchangeable
  • Show stock or availability

The patient, not the name

A useful alternative depends on the patient, not just the drug name.

Propranolol

  1. Choose a scenario
  2. Product identity
  3. Why the name is not enough
  4. What the prescriber decides
  5. The patient, not the name

Hypothetical supply scenario · every supply statement on this card is invented for the demonstration · no stock levels

Illustrative scenario · no patient record shown · considerations are general, not matched to a patient

A propranolol product is assumed unavailable. Hypothetical supply scenario for this demonstration. It does not describe current national supply.

The prescriber’s question

Why does the reason for propranolol change which alternatives a prescriber would weigh?

Product identity

  • Many indicationsPropranolol immediate-release tablets are licensed for several conditions, including migraine prophylaxis, most forms of cardiac dysrhythmias and prophylaxis of variceal bleeding in portal hypertension.Propranolol Hydrochloride 10 mg Film-coated tablets
One name, several products

Medicine namePropranolol

  • Propranolol Hydrochloride 10 mg Film-coated tablets

    “the control of most forms of cardiac dysrhythmias;”

    emc · §4.1 Therapeutic indications · source

  • Bedranol 80mg SR Capsules

    “a) Control of hypertension. b) Management of angina. c) Prophylaxis of migraine. d) Management of essential tremor. e) Management of anxiety. f) Adjunctive management of thyrotoxicosis.”

    emc · §4.1 Therapeutic indications · source

Listed in no order of preference. Each product has its own product information; whether one can stand in for another is the prescriber’s decision.

Why the drug name is not enough

About the patient

The indication sets the guidance

For migraine prevention, NICE CG150 discusses propranolol alongside other options; for hypertension, NICE NG136 notes beta-blockers are rarely used as step 1 treatment. Each indication leads to different guidance.

Source: Headaches in over 12s: diagnosis and management (CG150) · NICE (recommendations amended 2025); Hypertension in adults: diagnosis and management (NG136) · NICE

“Consider propranolol, topiramate or amitriptyline for migraine prevention”
Headaches in over 12s: diagnosis and management (CG150)NICE (recommendations amended 2025) · Prophylactic treatmentOpened 13 Nov 2026Open the source
“beta-blockers are rarely used as step 1 antihypertensive treatment in current practice”
Hypertension in adults: diagnosis and management (NG136)NICE · Rationale and impactOpened 13 Nov 2026Open the source

Respiratory history

A history of asthma or bronchospasm is a contraindication in the product literature.

Source: Propranolol Hydrochloride 10 mg Film-coated tablets — SmPC · emc

“Propranolol must not be used if there is a history of bronchial asthma or bronchospasm.”
Propranolol Hydrochloride 10 mg Film-coated tablets — SmPCemc · §4.3 Contraindications · revised 18/03/2026Opened 13 Nov 2026Open the source

Mental health history

NICE notes a risk of harm from propranolol in overdose for some patients.

Source: Headaches in over 12s: diagnosis and management (CG150) · NICE (recommendations amended 2025)

“People with depression and migraine could be at an increased risk of using propranolol for self-harm.”
Headaches in over 12s: diagnosis and management (CG150)NICE (recommendations amended 2025) · Prophylactic treatmentOpened 13 Nov 2026Open the source

About the product

Licensed indications differ by product

A modified-release capsule lists six indications; immediate-release tablets list more, including dysrhythmias and portal hypertension.

Source: Bedranol 80mg SR Capsules — SmPC · emc; Propranolol Hydrochloride 10 mg Film-coated tablets — SmPC · emc

“a) Control of hypertension. b) Management of angina. c) Prophylaxis of migraine. d) Management of essential tremor. e) Management of anxiety. f) Adjunctive management of thyrotoxicosis.”
Bedranol 80mg SR Capsules — SmPCemc · §4.1 Therapeutic indications · revised 11/03/2020Opened 13 Nov 2026Open the source
“the control of most forms of cardiac dysrhythmias;”
Propranolol Hydrochloride 10 mg Film-coated tablets — SmPCemc · §4.1 Therapeutic indications · revised 18/03/2026Opened 13 Nov 2026Open the source

What the prescriber decides

The prescriber decides

  • What the propranolol is for in this patient, from the record and the patient
  • Whether another propranolol product, another medicine or no change suits that indication
  • Monitoring and follow-up for the chosen course

Reedley does not

  • Choose, rank or match an alternative to the patient
  • Infer the indication when the record does not state it
  • Convert doses
  • Show stock or availability

The patient, not the name

A useful alternative depends on the patient, not just the drug name.

Illustrative scenarios · hypothetical supply situations, not current national supply · no patient record · no stock levels · Sources opened 13 Nov 2026 · Not connected to any clinical system

Illustrative demonstration · intended workflow · Scripted reconstruction: the development build itself is not running on this page.

  • Strength, formulation and release profile shown side by side.
  • Indication and patient history shown beside each consideration.
  • Four worked scenarios: spironolactone, venlafaxine, methylphenidate, propranolol.

From what arrives to what you decide

  1. What entersA medicine in short supply
  2. What Reedley preparesThe product and patient factors that matter, side by side
  3. What the clinician decidesThe prescriber chooses

What it does not do · what exists today

  • No alternative is selected or ranked for a patient.
  • No stock information is shown.
  • An illustration of intended workflow on four worked scenarios.
  • A working version would depend on national shortage notices (commercial access not yet established; no source examined gives live or local availability), dm+d product data and product information.
  • Not yet in Reedley’s intended-purpose register: shown to explore the workflow, not as committed product scope.

Every patient shown is synthetic. No integration with a clinical system is claimed, and no clinician has yet used Reedley in practice. Safety and governance

See it with your own work in mind.

Tell us your role and the workflows you care about, and we will walk you through them on synthetic data.